Chronic Myeloid Leukemia
More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.
Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.
Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.
There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.
Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
A large, long-term study found a 97% event-free survival rate at 18 months.
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.
For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.
Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.
ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 WeeksJune 25, 2018
Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage DiagnosisJune 19, 2018
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.
Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for InhibitionJune 18, 2018
Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.
Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.
Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.
There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.
Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.
Because most patients with CML are adults, there are no established treatment guidelines and many clinicians apply adult guidelines to their pediatric patients.
While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.
Previous studies have shown that first-line therapy with nilotinib, as well as switching to nilotinib after prolonged imatinib, may lead to higher rates of deep molecular response in chronic myeloid leukemia.
Targeted therapies among patients with chronic myeloid leukemia have improved over time, leading to patients achieving high rates of deep molecular response — a prerequisite criteria for tyrosine kinase inhibitor discontinuation.
Dasatinib 100 mg is currently approved for chronic myeloid leukemia but has been associated with high rates of adverse events.
Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.
View detailed treatment regimens for chronic myeloid leukemia (CML), with detailed instructions about primary treatment and follow-up treatment.
Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC